ACM
AQST icon

Altium Capital Management’s Aquestive Therapeutics AQST Stock Holding History

Altium Capital Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-665,000
Closed -$2.83M – 69
2024
Q1 		$2.83M Buy
+665,000
New +$2.21M 1.12% 30

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Altium Capital Management's AQST Position: Q2 2024 in Review

Altium Capital Management sold out of Aquestive Therapeutics (AQST) in Q2 2024, closing a stake of 665,000 shares — an estimated $2.83M sold.

Altium Capital Management first reported a position in AQST in Q1 2024 and held it in 1 quarter. The position peaked at $2.83M in Q1 2024. 97 funds tracked by Wall St. Rank hold AQST as of Q2 2024.

  • Altium Capital Management reported no remaining Aquestive Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Altium Capital Management sold 665,000 Aquestive Therapeutics shares in Q2 2024, an estimated $2.83M.
  • Altium Capital Management first reported a position in Aquestive Therapeutics in Q1 2024 and held it in 1 quarter.
  • Altium Capital Management's Aquestive Therapeutics position peaked at $2.83M in Q1 2024.
  • 97 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2024.

Based on Altium Capital Management's 13F filing for Q2 2024, filed 15 Aug 2024.